Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…
Biotechnology
US, Alameda [HQ]
Ratios
15 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | 96.43 | 91.86 | 89.52 | 96.58 | 96.67 | 96.91 | 96.58 | 96.33 | 96.32 | 96.41 | 96.04 | |
| Profit Margin | -89.10 | -49.90 | 26.14 | -311.16 | -781.03 | -1,069.42 | -456.63 | -36.68 | 34.09 | 80.82 | 33.17 | 11.32 | 16.10 | 11.31 | 11.35 | |
| Operating Margin | -80.33 | -49.39 | 30.91 | -258.03 | -640.54 | -893.86 | -326.65 | -14.69 | 36.67 | 51.40 | 38.18 | 11.14 | 19.98 | 12.51 | 9.34 | |
|
EPS Growth
|
18.18 | 32.54 | 170.59 | -253.33 | -44.57 | -3.76 | 41.30 | 65.43 | 285.71 | 346.15 | -54.31 | -66.04 | 102.78 | -21.92 | 14.04 | |
| EPS USD | -126.00 | -85.00 | 60.00 | -92.00 | -133.00 | -138.00 | -81.00 | -28.00 | 52.00 | 232.00 | 106.00 | 36.00 | 73.00 | 57.00 | 65.00 | |
| Return on Assets (ROA) | -39.38 | -25.59 | 19.25 | -20.48 | -48.63 | -81.88 | -51.07 | -11.75 | 23.54 | 48.52 | 17.02 | 5.23 | 8.83 | 5.93 | 7.06 | |
| Return on Equity (ROE) | 82.59 | 40.44 | 83.52 | -49.81 | -369.52 | 233.86 | 162.73 | -78.62 | 54.12 | 53.60 | 19.04 | 5.95 | 10.45 | 7.33 | 9.18 | |
| Return on Invested Capital (ROIC) | 143.62 | 459.69 | 32.35 | -19.38 | -48.53 | -90.88 | -43.83 | -14.71 | 45.20 | 49.38 | 17.15 | 4.87 | 9.99 | 5.81 | 5.56 | |
| Solvency | ||||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 23.18 | 57.78 | 46.16 | 46.56 | 68.99 | 110.27 | 114.77 | 31.65 | 10.99 | 4.85 | 2.69 | 2.44 | 1.63 | 6.77 | 7.33 | |
| Debt/Equity | -48.63 | -91.30 | 200.28 | 113.26 | 524.23 | -314.95 | -365.70 | 211.74 | 25.26 | 5.36 | 3.01 | 2.77 | 1.92 | 8.35 | 9.53 | |
| Debt/EBITDA | 5.96 | -231.42 | 106.06 | -156.94 | -122.69 | -132.35 | -199.89 | -167.52 | -100.84 | -66.93 | -58.40 | -245.44 | -207.87 | -154.37 | -37.16 | |
|
Debt/Capitalization
|
-94.66 | -1,049.27 | 66.70 | 53.11 | 83.98 | 146.52 | 137.64 | 67.92 | 20.17 | 5.09 | 2.92 | 2.70 | 1.89 | 7.71 | 8.70 | |
| Long-Term Debt/Capitalization | -32.72 | -296.29 | 66.09 | 52.11 | 83.51 | 177.82 | 137.64 | - - | 4.85 | 0.94 | 2.77 | 2.55 | 2.27 | 7.10 | 7.74 | |
| Interest Debt per Share USD | 0.86 | 2.01 | 1.57 | 2.27 | 2.13 | 2.11 | 2.06 | 0.89 | 0.27 | 0.23 | 0.17 | 0.17 | 0.14 | 0.48 | 0.68 | |
| Debt Growth | -32.34 | 161.83 | -12.93 | 84.96 | 3.43 | 4.15 | 5.47 | -50.42 | -92.32 | -16.19 | 316.65 | -3.26 | 4.45 | 270.90 | -0.12 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 111.05 | 91.77 | 247.85 | 529.40 | 303.47 | 97.31 | 341.94 | 173.99 | 421.01 | 850.48 | 708.38 | 706.25 | 543.48 | 499.06 | 334.27 | |
| Quick Ratio | 103.78 | 84.30 | 243.11 | 506.94 | 280.46 | 86.80 | 329.65 | 170.76 | 407.19 | 826.91 | 680.45 | 668.14 | 518.30 | 469.62 | 312.65 | |
| Cash Ratio | 41.91 | 48.73 | 80.43 | 208.15 | 118.35 | 46.78 | 271.06 | 56.06 | 159.04 | 298.44 | 186.70 | 155.98 | 191.70 | 154.52 | 66.70 | |
| Operating Cash Flow Ratio | - - | - - | -100 | -100 | -200 | -100 | -200 | - - | 100 | 300 | 300 | 100 | 100 | 100 | - - | |
| Turnover | ||||||||||||||||
| Inventory Turnover | - - | - - | - - | - - | 38.69 | 85.80 | 148.89 | 196.29 | 226.32 | 267.82 | 256.85 | 172.95 | 192.31 | 173.91 | 418.79 | |
| Receivables Turnover | 1,279.16 | 3,138.48 | 959.38 | 1,724.83 | 795.18 | 514.36 | 717.19 | 453.19 | 557.29 | 477.46 | 812.76 | 613.85 | 507.68 | 750.09 | 770.92 | |
| Payables Turnover | - - | - - | - - | - - | 11.96 | 31.86 | 60.85 | 99.80 | 157.35 | 241.70 | 285.79 | 153.49 | 217.96 | 177.27 | 214.84 | |
|
Asset Turnover
|
44.19 | 51.29 | 73.65 | 6.58 | 6.23 | 7.66 | 11.18 | 32.04 | 69.05 | 60.03 | 51.32 | 46.20 | 54.85 | 52.45 | 62.20 | |
| Fixed Turnover | 516.33 | 1,170.36 | 3,405.08 | 783.13 | 638.25 | 1,032.52 | 2,592.19 | 9,244.52 | 1,757.67 | 1,504.17 | 1,066.69 | 1,465.54 | 1,379.37 | 401.56 | 388.70 | |
| Coverage | ||||||||||||||||
| Interest Coverage | -962.02 | -978.55 | 550.68 | -451.99 | -442.66 | -461.78 | -249.46 | -85.07 | 1,911.63 | - - | - - | - - | - - | -374.90 | - - | |
| Asset Coverage | 200 | - - | 100 | 100 | 100 | - - | - - | 200 | 4,100 | 11,200 | 3,400 | 3,900 | 4,400 | 1,400 | 1,300 | |
| Cash Flow Coverage (CFGR) | -18.33 | -48.47 | -87.72 | -36.68 | -57.24 | -65.09 | -37.12 | 109.08 | 230.04 | 602.26 | 1,038.56 | 401.03 | 942.34 | 174.48 | 154.56 | |
| EBITDA Coverage | -900 | -500 | 600 | -300 | -400 | -400 | -200 | - - | 1,900 | - - | - - | - - | - - | -300 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | 100 | - - | - - | - - | - - | - - | 100 | 200 | 100 | 100 | 100 | 100 | 100 | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -17.14 | -10.36 | 12.69 | -20.44 | -21.70 | -95.98 | -14.38 | -1.88 | 1.73 | 11.92 | 6.24 | 1.81 | 4.01 | 3.53 | 2.72 | |
|
Price/Earnings (P/E)
|
-583.59 | -964.98 | 788.27 | -489.16 | -460.90 | -104.19 | -695.22 | -5,319.44 | 5,786.97 | 839.19 | 1,603.35 | 5,534.93 | 2,491.13 | 2,829.28 | 3,673.59 | |
| Price/Earnings Growth (PEG) | 32.10 | 29.66 | -4.62 | 1.93 | -10.34 | -27.71 | 16.83 | 81.30 | -20.25 | 2.42 | -29.52 | -83.81 | 24.24 | -129.09 | 261.74 | |
|
Price/Book (P/B)
|
-481.98 | -390.22 | 658.37 | 243.64 | 1,703.11 | -243.66 | -1,131.35 | 4,182.16 | 3,132.03 | 449.80 | 305.28 | 329.25 | 260.38 | 207.25 | 337.14 | |
| Price/Tangible Book (P/TB) | -481.98 | -390.22 | 658.37 | 243.64 | 1,703.11 | -243.66 | -1,131.35 | 4,182.16 | 3,132.03 | 449.80 | 305.28 | 329.25 | 260.38 | 207.25 | 337.14 | |
| Price/Sales (P/S) | 519.99 | 481.49 | 206.02 | 1,522.07 | 3,599.80 | 1,114.22 | 3,174.54 | 1,951.08 | 1,972.49 | 678.24 | 531.83 | 626.51 | 401.13 | 320.12 | 417.03 | |
|
Price/Cash Flow (P/CF)
|
-5,408.32 | -881.73 | -374.73 | -586.48 | -567.53 | -118.85 | -833.45 | 1,810.71 | 5,389.18 | 1,393.01 | 976.73 | 2,960.54 | 1,436.13 | 1,422.25 | 2,289.80 | |
| Price/Free CF (P/FCF) | -3,849.59 | -866.20 | -372.41 | -573.82 | -561.40 | -118.62 | -830.83 | 1,825.78 | 6,177.89 | 1,514.30 | 1,001.12 | 3,463.45 | 1,710.17 | 2,300.73 | 4,480.32 | |
| Price/Operating CF (P/OCF) | -5,408.32 | -881.73 | -374.73 | -586.48 | -567.53 | -118.85 | -833.45 | 1,810.71 | 5,389.18 | 1,393.01 | 976.73 | 2,960.54 | 1,436.13 | 1,422.25 | 2,289.80 |